{"output": [["Recro Pharma, Inc.", "COMP", "Announce", "Several Key Promotions", "ORG"], ["Michael Celano", "PERSON", "Promoted_To", "Chief Operating Officer", "ORG"], ["Ryan D. Lake", "PERSON", "Promoted_To", "Chief Financial Officer", "ORG"], ["Michael Celano", "PERSON", "Operate_In", "CDMO Division", "ORG"], ["Michael Celano", "PERSON", "Lead", "Finance and Administration", "ORG"], ["Michael Celano", "PERSON", "Join", "Recro", "COMP", "July", "2016"], ["Michael Celano", "PERSON", "Serve", "Kensey Nash", "COMP", "Partner", "Arthur Andersen/KPMG"], ["Ryan D. Lake", "PERSON", "Join", "Recro", "COMP", "June", "2017"], ["Ryan D. Lake", "PERSON", "Serve", "Aspire Bariatrics", "COMP", "CFO"], ["Ryan D. Lake", "PERSON", "Hold", "Executive Management and Senior Finance Positions", "ORG", "DSM Biomedical"], ["Ryan D. Lake", "PERSON", "Hold", "Various Senior Financial Positions", "ORG", "Kensey Nash"], ["Recro Pharma, Inc.", "COMP", "Operate_In", "Acute Care, Hospital Product Division", "ORG"], ["Recro Pharma, Inc.", "COMP", "Operate_In", "CDMO Division", "ORG"], ["Recro Pharma, Inc.", "COMP", "Develop", "Innovative Products", "PRODUCT", "Acute Care, Hospital Setting"], ["Recro Pharma, Inc.", "COMP", "Lead", "Product Candidate", "PRODUCT", "Injectable Form of Meloxicam"], ["Recro Pharma, Inc.", "COMP", "Have", "Acute Care Division", "ORG"], ["Recro Pharma, Inc.", "COMP", "Have", "CDMO Division", "ORG"], ["Injectable Meloxicam", "PRODUCT", "Undergo", "Phase III Clinical Efficacy Trials", "EVENT"], ["Injectable Meloxicam", "PRODUCT", "Undergo", "Phase II Clinical Trials", "EVENT"], ["Injectable Meloxicam", "PRODUCT", "Undergo", "Safety Studies", "EVENT"], ["Injectable Meloxicam", "PRODUCT", "Have", "No Addictive Potential", "CONCEPT"], ["Injectable Meloxicam", "PRODUCT", "Maintain", "Meaningful Analgesic Effects", "CONCEPT"], ["Injectable Meloxicam", "PRODUCT", "Relate_To", "Pain Management", "CONCEPT"], ["Injectable Meloxicam", "PRODUCT", "Overcome", "Issues Associated with Commonly Prescribed Opioid Therapeutics", "CONCEPT"], ["Injectable Meloxicam", "PRODUCT", "Have", "Non-Opioid Class of Drugs", "CONCEPT"], ["Recro Pharma, Inc.", "COMP", "Have", "Contract Development and Manufacturing Division", "ORG"], ["Recro Pharma, Inc.", "COMP", "Leverage", "Formulation Expertise", "CONCEPT"], ["Recro Pharma, Inc.", "COMP", "Develop and Manufacture", "Pharmaceutical Products", "PRODUCT"], ["Recro Pharma, Inc.", "COMP", "Provide", "Manufacturing Services", "SERVICE", "Commercial Partners"], ["Recro Pharma, Inc.", "COMP", "Generate", "Revenue Streams", "FIN_INSTRUMENT"], ["Recro Pharma, Inc.", "COMP", "Contribute", "Non-Dilutive Funding", "FIN_INSTRUMENT"], ["Recro Pharma, Inc.", "COMP", "Have", "Acute Care Division", "ORG"], ["Recro Pharma, Inc.", "COMP", "Have", "CDMO Division", "ORG"]], "published": "2018-01-03T15:00:00.000+02:00"}